SCHEMBL4862311

SCHEMBL4862311

Cc1ccc(NC(=N)c2ccccc2)cc1C

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.61
KMT2A Q03164 6/20 0.61
NPC1 O15118 5/20 0.61
MEN1 O00255 5/20 0.58
FKBP5 Q13451 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 2/20 0.53
MAPT P10636 2/20 0.53
CYP1A2 P05177 1/20 0.51
POLB P06746 1/20 0.49
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP3A4 P08684 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4855896 0.81 RAB9A (0.70) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL4858644 0.80 RAB9A (0.51) RAB9AKMT2ANPC1MEN1FKBP5
SCHEMBL3366766 0.80 ESR1 (0.45) RAB9AKMT2ANPC1MEN1FKBP5
SCHEMBL4853047 0.79 NPC1 (0.61) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28622654 0.79 RAB9A (0.93) RAB9AKMT2ANPC1MEN1FKBP5
SCHEMBL29707145 0.79 MEN1 (0.57) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28448195 0.79 MEN1 (0.57) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL23332259 0.78 NPC1 (0.52) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28294635 0.78 THRB (0.53) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL4853081 0.78 PKM (0.46) RAB9AKMT2ANPC1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP RAB9A 2079/4885KMT2A 4298/4885NPC1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.